July 25, 2017 7:24 AM ET


Company Overview of InnaVirVax SAS

Company Overview

InnaVirVax SAS operates as a biopharmaceutical company. It develops therapeutic vaccines and biotherapy for HIV infection, and prognostic tests for predicting the rate of progression towards AIDS in HIV-infected asymptomatic patients, as well as develops cancer biotherapy products. The company was incorporated in 2008 and is based in Evry, France.

Genopole Entreprises - CAMPUS 1

4 rue Pierre Fontaine


Evry,  91058


Founded in 2008


33 1 80 85 60 83


33 1 80 85 60 87

Key Executives for InnaVirVax SAS

Co-Founder, Chief Executive Officer and Chief Scientific Officer
Co-Founder and Scientific Advisor
Age: 73
Co-Founder and Scientific Advisor
Age: 79
Compensation as of Fiscal Year 2017.

InnaVirVax SAS Key Developments

InnaVirVax SAS Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

InnaVirVax SAS Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.

FIT Biotech Partners with InnaVirVax for HIV Immunotherapy Clinical Development and Commercialization

FIT Biotech and InnaVirVax announced a collaboration in HIV-treatment combining their proprietary immunotherapeutic HIV-vaccines having a different mode of action with a potentially synergistic effect in functional HIV-cure. Functional HIV-cure is defined as a sustained remission of HIV-infection without the need for continuous treatment with chemical drugs, and no disease progression. FIT Biotech and InnaVirVax plan to start a phase II trial in 2017 to evaluate the safety, tolerability, immunogenicity and clinical efficacy of FIT Biotech's DNA-based HIV-vaccine in combination with InnaVirVax's immunoprotective vaccine. InnaVirVax will conduct and fund the clinical study in return for co-ownership of the immunotherapy. Upon successful completion of the study, the companies plan to jointly seek additional third party support and resources to further develop and commercialize the combination of the two products.

InnaVirVax SAS Presents at 15th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-29-2015 through Sep-30-2015

InnaVirVax SAS Presents at 15th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-29-2015 through Sep-30-2015. Venue: Congress Center, Basel, Switzerland. Presentation Date & Speakers: Sep-29-2015, Joël Crouzet, Co-Founder, Chief Executive Officer and Chief Scientific Officer.

Similar Private Companies By Industry

Company Name Region
4P Pharma Europe
A.T.O. ZIZINE S.A.S Europe
Advicenne Pharma Europe
Aerocid Europe
AG Pharma Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact InnaVirVax SAS, please visit www.innavirvax.fr. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.